ArticleCancer causes & control : CCC2026
Second primary cancers among females with a first primary cervical, uterine and ovarian cancer: a population-based study in North Portugal.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo estimate the incidence rates of second primary cancers (SCPs) [diagnosed > 2 months after a first primary cancer (FPC)], and cumulative incidence and mortality of metachronous SPCs in patients with a cervical, uterine, or ovarian FPC, and to compare the incidence of SPCs with that expected in the general female population.
methodsA cohort of patients with cervical, uterine, or ovarian FPC from the North Region Cancer Registry of Portugal, diagnosed in 2000-2010 (n = 5846) was followed until 31/12/2015 for synchronous and metachronous SPCs. Cumulative incidence of metachronous SPCs considering death as a competing event, and incidence rates and standardized incidence ratios (SIR) of SPCs were estimated.
resultsDiagnosis of an SPC occurred in 541 (9.3%) patients at a median age of 60 years. SPCs were more frequent among patients with uterine cancers. Colon, breast, and corpus uteri were the most common sites for an SPC among patients with a gynecological FPC. A higher incidence of all and individual SPCs compared to the general female population was found (SIR = 1.96, 95% CI 1.79-2.12) with the most relevant sites being cancers of the colon (SIR = 2.32, 95% CI 1.82-2.89), lung (SIR = 2.70, 95% CI 1.88, 3.66), cervix (SIR = 4.87, 95% CI 3.43, 6.56), corpus uteri (SIR = 5.37, 95% CI 4.16, 6.73) and ovary (SIR = 6.06, 95% CI 4.12-8.37). The 10-year cumulative incidence of a metachronous SPC and death for patients with a gynecological FPC was 7.4% and 39.2%, respectively.
conclusionIn Portugal, patients with a gynecological FPC have a higher incidence of SPCs compared to the general female population, particularly elderly females. Increased surveillance and counselling among these patients are needed.
Indexed as
Identifiers
42518015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.